References of "Lefebvre, P. J"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity
Damas, Jacques ULg; Garbacki, Nancy ULg; Lefèbvre, P. J.

in Diabetes/Metabolism Research & Reviews (2004), 20(4, Jul-Aug), 288-297

The therapeutic use of angiotensin converting enzyme (ACE) inhibitors, at a large scale, in arterial hypertension has showed that these molecules can exert, beneficial effects on insulin sensitivity and ... [more ▼]

The therapeutic use of angiotensin converting enzyme (ACE) inhibitors, at a large scale, in arterial hypertension has showed that these molecules can exert, beneficial effects on insulin sensitivity and may reduce the occurrence of type 2 diabetes mellitus. One hypothesis explaining these effects of ACE inhibitors may relate to their capacity to interfere with bradykinin (BK) metabolism and action. BK may participate in the regulation of substrate utilization by, several tissues by improving blood flow and substrate delivery to the tissues and also by promoting translocation of glucose transporters. Moreover, BK has been shown to increase phosphorylation of insulin receptor and its cell substrates. BK also appears to improve the release of insulin. Furthermore, insulin may activate the kallikrein-kinin system, which consequently may increase its metabolic effects. However, in experimental diabetes mellitus, BK can participate to the inflammatory reaction leading to Langerhans islets destruction. In diabetes, whereas tissue kallikrein mRNA levels were reduced in several organs, an overexpression of kinin receptors, an increase in plasma levels of kininogens and kallikrein and an activation of the kinin system have all been reported. Lastly, kinins may be involved in the development of diabetic nephropathy. Reduction of kinin metabolism by ACE inhibitors might be involved in the beneficial effects exerted by these compounds in diabetic kidney functions. Copyright (C) 2004 John Wiley Sons, Ltd. [less ▲]

Detailed reference viewed: 28 (1 ULg)
Full Text
Peer Reviewed
See detailThe Intrathymic Expression of Insulin-Related Genes: Implications for Pathophysiology and Prevention of Type 1 Diabetes
Geenen, Vincent ULg; Lefebvre, P. J.

in Diabetes/Metabolism Reviews (1998), 14(1), 95-103

Recent experimental work has challenged and shattered the old concept of a sequestration of pancreatic islet antigens from developing T-cells within the thymic environment. There is now compelling ... [more ▼]

Recent experimental work has challenged and shattered the old concept of a sequestration of pancreatic islet antigens from developing T-cells within the thymic environment. There is now compelling evidence that the central immunological tolerance of the whole insulin family may be induced during the process of T-cell ontogeny in the thymus. Transcripts of insulin-like growth factor II (IGF-II), IGF-I and insulin genes have been characterized in human, rat and mouse thymuses. At the peptide level, IGF-II was shown to be the dominant polypeptide of the insulin family in the thymus from different species. Data are presented which support a dual role of thymic IGF-II both in T-cell development as well as in T-cell negative selection. Using animal models of autoimmune diabetes, current research is investigating the hypothesis that a defect of thymic T-cell education to the insulin family is implicated in the pathophysiology of human Type 1 diabetes. An efficient and secure prevention of Type 1 diabetes could be designed on the basis of the strong natural tolerogenic properties of the thymus. [less ▲]

Detailed reference viewed: 27 (0 ULg)
Peer Reviewed
See detailComment j'explore ... nouveaux critères pour le diagnostic du diabète sucré
Scheen, A. J.; Paquot, Nicolas ULg; Lefebvre, P. J.

in Revue Médicale de Liège (1997), 52(9), 606-9

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailLa dépense énergétique chez l'homme
Bustin, F.; Pestieau, S. R.; Paquot, Nicolas ULg et al

in Revue Médicale de Liège (1997), 52(2), 101-4

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailEffects of Ingested Fructose and Infused Glucagon on Endogenous Glucose Production in Obese Niddm Patients, Obese Non-Diabetic Subjects, and Healthy Subjects
Paquot, Nicolas ULg; Schneiter, P.; Jequier, E. et al

in Diabetologia (1996), 39(5), 580-6

Increased endogenous glucose production (EGP) and gluconeogenesis contribute to the pathogenesis of hyperglycaemia in non-insulin-dependent diabetes mellitus (NIDDM). In healthy subjects, however, EGP ... [more ▼]

Increased endogenous glucose production (EGP) and gluconeogenesis contribute to the pathogenesis of hyperglycaemia in non-insulin-dependent diabetes mellitus (NIDDM). In healthy subjects, however, EGP remains constant during administration of gluconeogenic precursors. This study was performed in order to determine whether administration of fructose increases EGP in obese NIDDM patients and obese non-diabetic subjects. Eight young healthy lean subjects, eight middle-aged obese NIDDM patients and seven middle-aged obese non-diabetic subjects were studied during hourly ingestion of 13C fructose (0.3 g.kg fat free mass-1.h-1) for 3 h. Fructose failed to increase EGP (measured with 6,6 2H glucose) in NIDDM (17.7 +/- 1.9 mumol.kg fat free mass-1.min-1 basal vs 15.9 +/- 0.9 after fructose), in obese non-diabetic subjects (12.1 +/- 0.5 basal vs 13.1 +/- 0.5 after fructose) and in lean healthy subjects (13.3 +/- 0.5 basal vs 13.8 +/- 0.6 after fructose) although 13C glucose synthesis contributed 73.2% of EGP in lean subjects, 62.6% in obese non-diabetic subjects, and 52.8% in obese NIDDM patients. Since glucagon may play an important role in the development of hyperglycaemia in NIDDM, healthy subjects were also studied during 13C fructose ingestion + hyperglucagonaemia (232 +/- 9 ng/l) and during hyperglucagonaemia alone. EGP increased by 19.8% with ingestion of fructose + glucagon (p < 0.05) but remained unchanged during administration of fructose or glucagon alone. The plasma 13C glucose enrichment was identical after fructose ingestion both with and without glucagon, indicating that the contribution of fructose gluconeogenesis to the glucose 6-phosphate pool was identical in these two conditions. We concluded that during fructose administration: 1) gluconeogenesis is increased, but EGP remains constant in NIDDM, obese non-diabetic, and lean individuals; 2) in lean individuals, both an increased glucagonaemia and an enhanced supply of gluconeogenic precursors are required to increase EGP; this increase in EGP occurs without changes in the relative proportion of glucose 6-phosphate production from fructose and from other sources (i.e. glycogenolysis + gluconeogenesis from non-fructose precursors). [less ▲]

Detailed reference viewed: 37 (0 ULg)
Peer Reviewed
See detailComment évaluer la sécrétion insulinique en pratique?
Scheen, A. J.; Paquot, Nicolas ULg; Letiexhe, M. R. et al

in Diabète & Métabolisme (1995), 21(6), 458-64

Detailed reference viewed: 8 (0 ULg)
Peer Reviewed
See detailLe cas clinique du mois. Rémission spontanée prolongée d'un diabète de type 1 typique
Scheen, A. J.; Letiexhe, M. R.; Paquot, Nicolas ULg et al

in Revue Médicale de Liège (1995), 50(9), 363-4

Detailed reference viewed: 32 (0 ULg)
Peer Reviewed
See detailHow to Measure Insulin Action in Vivo
Scheen, A. J.; Paquot, Nicolas ULg; Castillo, M. J. et al

in Diabetes/Metabolism Reviews (1994), 10(2), 151-88

Detailed reference viewed: 15 (0 ULg)
Peer Reviewed
See detailLe diabète de type 2 insulinorequérant: caractéristiques des patients et effets de l'insulinothérapie
Duysinx, Bernard ULg; Scheen, A. J.; Paquot, Nicolas ULg et al

in Revue Médicale de Liège (1994), 49(6), 305-23

Detailed reference viewed: 39 (0 ULg)
Peer Reviewed
See detailComment évaluer la sensibilité à l'insuline en pratique?
Scheen, A. J.; Paquot, Nicolas ULg; Letiexhe, M. R. et al

in Diabète & Métabolisme (1994), 20(6, Nov-Dec), 556-61

Detailed reference viewed: 10 (0 ULg)
Peer Reviewed
See detailPathogenic Tracks in Fatigue Syndromes
Moutschen, Michel ULg; Triffaux, Jean-Marc ULg; Demonty, Jean ULg et al

in Acta Clinica Belgica (1994), 49(6), 274-89

This review analyses the recent literature devoted to two related fatigue syndromes: chronic fatigue syndrome (CFS) and acute onset postviral fatigue syndrome (PVFS). The articles are grouped into five ... [more ▼]

This review analyses the recent literature devoted to two related fatigue syndromes: chronic fatigue syndrome (CFS) and acute onset postviral fatigue syndrome (PVFS). The articles are grouped into five pathogenic tracks: infectious agents, immune system, skeletic muscle, hypothalamo-pituitary-adrenal (HPA) axis and psychiatric factors. Although a particular infectious agent is unlikely to be responsible for all CFS cases, evidence is shown that host-parasite relationships are modified in a large proportion of patients with chronic fatigue. Antibody titres against infectious agents are often elevated and replication of several viruses could be increased. Chronic activation of the immune system is also observed and could be due to the reactivation of persistent or latent infectious agents such as herpes viruses (i.e. HHV-6) or enteroviruses. It could also be favorised by an impaired negative feedback of the HPA axis on the immune system. A model is proposed where the abnormalities of the HPA axis are primary events and are mainly responsible for a chronic activation of the immune system which in turn induces an increased replication of several viruses under the control of cellular transcription factors. These replicating viruses together with cytokines such as TNF-alpha would secondarily induce functional disorders of muscle and several aspects of asthenia itself. [less ▲]

Detailed reference viewed: 23 (5 ULg)
Peer Reviewed
See detailTransfert des insulines U40 aux insulines U100: comparaison des profils insulinémiques et glycémiques chez le patient diabétique
Scheen, A. J.; Guiot, Julien; Stassen, M. P. et al

in Revue Médicale de Liège (1991), 46(4), 181-7

Detailed reference viewed: 8 (0 ULg)
Peer Reviewed
See detailLa cellule beta dans le diabète de type II: coupable ou victime?
SCHEEN, André ULg; Paquot, Nicolas ULg; Lefebvre, P. J.

in Journées Annuelles de Diabetologie de l'Hôtel-Dieu (1991)

Detailed reference viewed: 10 (0 ULg)